Study identifier:D5010C00008
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Single-Center, Randomized, Double-Blinded, Placebo-Controlled, 4-way Cross-over Study to Assess the Effect of a Single Oral Dose of AZD3293 Administration on QTc Interval Compared to Placebo, Using Open-Label AVELOX (moxifloxacin) as a Positive Control, in Healthy Male Subjects
Alzheimer's disease
Phase 1
Yes
AZD3293, Placebo, Moxifloxacin
Male
52
Interventional
18 Years - 55 Years
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verified 01 Jul 2014 by AstraZeneca
AstraZeneca
PAREXEL
A thorough QT study of AZD3293
A Single-Center, Randomized, Double-Blinded, Placebo-Controlled, 4-way Cross-over Study to Assess the Effect of a Single Oral Dose of AZD3293 Administration on QTc Interval Compared to Placebo, Using Open-Label AVELOX (moxifloxacin) as a Positive Control, in Healthy Male Subjects
Location
Location
Baltimore, MD, United States
Arms | Assigned Interventions |
---|---|
Experimental: AZD3293 dose A AZD3293 therapeutic dose oral solution (low dose) | Drug: AZD3293 AZD3293 oral solution - one single dose (low dose). Other Name: beta secretase inhibitor |
Experimental: AZD3293 dose B AZD3293 supratherapeutic dose oral solution (high dose) | Drug: AZD3293 AZD3293 oral solution - one single dose (high dose). Other Name: Not applicable |
Placebo Comparator: Placebo Placebo oral solution | Drug: Placebo Placebo oral solution - one single dose Other Name: Not applicable |
Active Comparator: Moxifloxacin Moxifloxacin tablet | Drug: Moxifloxacin Moxifloxacin tablet - one single dose Other Name: Not applicable |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.